Abstract
Osteosarcoma is a malignant tumor that originates in the bones with the characteristics of high malignancy, predisposition to metastasis, and poor prognosis. RNA binding proteins (RBPs) are closely related to various tumors, but their relationship with osteosarcoma remains unclear. Based on GTEx and TARGET RNA sequencing data, we applied differential analysis to obtain RBP genes that are differentially expressed in osteosarcoma, and analyzed the functions of these RBPs. After applying univariate and LASSO Cox regression analysis, 10 key prognostic RBPs (TDRD6, TLR8, NXT2, EIF4E3, RPS27L, CPEB3, RBM34, TERT, RPS29, and ZC3HAV1) were screened, and an RBP prognostic risk assessment model for patients with osteosarcoma was established. The independent cohort GSE21257 was used for external verification, and the results showed that the signature has an excellent ability to predict prognosis. In addition, a nomogram that can be used for clinical evaluation was constructed. Finally, the expression levels of 10 prognostic RBPs in osteosarcoma cells and tissues were confirmed through experiments. Our study identified a ten-gene prognostic marker related to RBP, which is of great significance for adjusting the treatment strategy of patients with osteosarcoma and exploring prognostic markers.
Highlights
Osteosarcoma is most common in adolescents (Arndt and Crist, 1999; Gianferante et al, 2017)
Our results showed that compared with osteoblasts, Cytoplasmic polyadenylation element-binding protein 3 (CPEB3), EIF4E3, RBM34, Ribosomal protein S27-like (RPS27L), RPS29 and TDRD6 were down-regulated in U2OS and 143B, while NXT2, Telomerase reverse transcriptase (TERT), TLR8 and ZC3HAV1 were up-regulated in osteosarcoma cells (Figure 7A)
It is of great significance to study the clinical value and potential molecular mechanisms of RNA binding proteins (RBPs)-related genes in osteosarcoma
Summary
Osteosarcoma is most common in adolescents (Arndt and Crist, 1999; Gianferante et al, 2017). It is highly malignant, progresses quickly, and has a poor prognosis, which seriously affects family and social health (Stiller et al, 2006). Treatment of osteosarcoma was mostly based on amputation, but the prognosis was poor (Fletcher et al, 2002). Subsequent chemotherapy improved the patient’s prognosis (Ritter and Bielack, 2010). The 5 years survival rate of patients with metastatic osteosarcoma is
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
